Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × liposomal doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 90 Breast Neoplasms 68 Fallopian Tube Neoplasms 36 Multiple Myeloma 26 Carcinoma, Ovarian Epithelial 24 Neoplasms 22 Triple Negative Breast Neoplasms 13 Lymphoma 13 Sarcoma 12 Neoplasm Metastasis 11 Lymphoma, Large B-Cell, Diffuse 9 Recurrence 8 Lymphoma, Non-Hodgkin 7 Hodgkin Disease 7 Prostatic Neoplasms 6 Pancreatic Neoplasms 5 Neoplasms, Plasma Cell 5 Burkitt Lymphoma 5 Solid Tumors 4 Sarcoma, Kaposi 4 Sarcoma, Ewing 4 Lymphoma, T-Cell, Peripheral 4 Carcinoma 4 Breast Neoplasms, Male 4 Uterine Cervical Neoplasms 3 Rhabdomyosarcoma 3 Osteosarcoma 3 Lymphoma, T-Cell 3 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡